Regenxbio Good News for wet AMD
On January 10, 2022, Regenxbio Inc. (RGNX) announced the initiation of ASCENT, the second of two Phase 3 pivotal trials to evaluate the efficacy and safety of subretinal delivery of RGX-314 in patients with wet age-related macular degeneration (wet AMD).
RGX-314 is being investigated as a potential one-time gene therapy for . . .
This content is for paid subscribers.
Impacting News February 8, 2022